HK1110803A1 - Use of baff to treat th2-mediated conditions - Google Patents

Use of baff to treat th2-mediated conditions

Info

Publication number
HK1110803A1
HK1110803A1 HK08105606.7A HK08105606A HK1110803A1 HK 1110803 A1 HK1110803 A1 HK 1110803A1 HK 08105606 A HK08105606 A HK 08105606A HK 1110803 A1 HK1110803 A1 HK 1110803A1
Authority
HK
Hong Kong
Prior art keywords
baff
treat
mediated conditions
mediated
conditions
Prior art date
Application number
HK08105606.7A
Other languages
English (en)
Inventor
Charles Mackay
Fabienne Mackay
Susan Kalled
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of HK1110803A1 publication Critical patent/HK1110803A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08105606.7A 2005-01-28 2008-05-21 Use of baff to treat th2-mediated conditions HK1110803A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64809805P 2005-01-28 2005-01-28
PCT/US2006/003127 WO2006081516A2 (en) 2005-01-28 2006-01-27 USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS

Publications (1)

Publication Number Publication Date
HK1110803A1 true HK1110803A1 (en) 2008-07-25

Family

ID=36741125

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105606.7A HK1110803A1 (en) 2005-01-28 2008-05-21 Use of baff to treat th2-mediated conditions

Country Status (9)

Country Link
US (1) US20080254030A1 (da)
EP (1) EP1855711B1 (da)
AU (1) AU2006209237B2 (da)
CA (1) CA2596276A1 (da)
DE (1) DE602006007323D1 (da)
DK (1) DK1855711T3 (da)
HK (1) HK1110803A1 (da)
NZ (1) NZ560285A (da)
WO (1) WO2006081516A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE494304T1 (de) * 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
WO2002016411A2 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US20070086979A1 (en) * 2005-10-13 2007-04-19 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) * 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
US8735347B2 (en) 2011-02-02 2014-05-27 Children's Hospital Medical Center Regulation of energy metabolism and obesity by modulating B cell activating factor (BAFF, BLYS) or BAFF signaling

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20030022239A1 (en) * 1997-06-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020055624A1 (en) * 1997-11-17 2002-05-09 Steven R. Wiley Tnf-delta ligand and uses thereof
US20010010925A1 (en) * 1997-11-17 2001-08-02 Steven R. Wiley Methods of detecting target nucleic acids of tnf-delta
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
EP1415659B9 (en) * 1999-01-25 2012-02-15 Biogen Idec MA Inc. An antibody specific for soluble BAFF for use in the treatment of cancer
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
US6475987B1 (en) * 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
KR20090016772A (ko) * 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2897626C (en) * 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Heterologous polypeptide of the tnf family
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
ATE494304T1 (de) * 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
US6475686B2 (en) * 2000-07-28 2002-11-05 Canon Kabushiki Kaisha Fixing method
WO2002016411A2 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP4660092B2 (ja) * 2001-12-21 2011-03-30 イミユネツクス・コーポレイシヨン 組換えポリペプチド
US20030211509A1 (en) * 2002-03-26 2003-11-13 Wiley Steven R. TNF-delta ligand and uses thereof

Also Published As

Publication number Publication date
DE602006007323D1 (de) 2009-07-30
NZ560285A (en) 2011-04-29
WO2006081516A3 (en) 2007-05-03
AU2006209237B2 (en) 2010-06-24
CA2596276A1 (en) 2006-08-03
WO2006081516A2 (en) 2006-08-03
US20080254030A1 (en) 2008-10-16
EP1855711B1 (en) 2009-06-17
AU2006209237A1 (en) 2006-08-03
EP1855711A2 (en) 2007-11-21
DK1855711T3 (da) 2009-10-12

Similar Documents

Publication Publication Date Title
HK1110803A1 (en) Use of baff to treat th2-mediated conditions
AU2007208169A8 (en) Use of gallium to treat biofilm-associated infectons
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
ZA200710598B (en) Treatment of inflammatory conditions
PL2049132T3 (pl) Nowe środki do leczenia zaburzeń związanych z osłabionym neuroprzekaźnictwem
IL189602A0 (en) Indenoisoquinolinone analogs and methods of use thereof
GB0605337D0 (en) Treatment of CNS conditions
MY145179A (en) Use of tetrahydrobenzoxazines as stabilizers
ZA200900886B (en) Use of azabicyclo hexane derivatives
IL185757A0 (en) Methods of decreasing calcifcation
IL187715A0 (en) Use of phenylsemicarbazones for seed treatment
HK1161122A1 (en) Use of 24-norudca 24-norudca
GB0518508D0 (en) Treatment of waste
GB2431154B (en) Purification treatment of water
EP1926824A4 (en) METHOD FOR DETERMINING REACTIVITY TO ERYTROPOIETIN TREATMENT
GB0605715D0 (en) Treatment of laminitis
IL210489A0 (en) Use of hdac inhibitors for the treatment of hodgkin's disease
GB0515035D0 (en) Treatment of atherosclerotic conditions
IL185114A0 (en) Use of vitamin d compounds to treat endometriosis
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
ZA200607681B (en) Treatment of water
ZA200800393B (en) Use of phenylsemicarbazones for seed treatment
GB0602857D0 (en) The treatment of sialorrhoea
GB0518003D0 (en) Treatment of hepatatis c
ZA200802337B (en) Treatment of water